178 related articles for article (PubMed ID: 36359470)
1. Metabolomic Signature of Diabetic Kidney Disease in Cerebrospinal Fluid and Plasma of Patients with Type 2 Diabetes Using Liquid Chromatography-Mass Spectrometry.
Lin HT; Cheng ML; Lo CJ; Lin G; Liu FC
Diagnostics (Basel); 2022 Oct; 12(11):. PubMed ID: 36359470
[TBL] [Abstract][Full Text] [Related]
2. Impaired Amino Acid Metabolism and Its Correlation with Diabetic Kidney Disease Progression in Type 2 Diabetes Mellitus.
Zhu H; Bai M; Xie X; Wang J; Weng C; Dai H; Chen J; Han F; Lin W
Nutrients; 2022 Aug; 14(16):. PubMed ID: 36014850
[TBL] [Abstract][Full Text] [Related]
3. Metabolomic Profiling of Amino Acids in Human Plasma Distinguishes Diabetic Kidney Disease From Type 2 Diabetes Mellitus.
Zhou C; Zhang Q; Lu L; Wang J; Liu D; Liu Z
Front Med (Lausanne); 2021; 8():765873. PubMed ID: 34912824
[No Abstract] [Full Text] [Related]
4. Profiling of Plasma Metabolites Suggests Altered Mitochondrial Fuel Usage and Remodeling of Sphingolipid Metabolism in Individuals With Type 2 Diabetes and Kidney Disease.
Liu JJ; Ghosh S; Kovalik JP; Ching J; Choi HW; Tavintharan S; Ong CN; Sum CF; Summers SA; Tai ES; Lim SC
Kidney Int Rep; 2017 May; 2(3):470-480. PubMed ID: 29142974
[TBL] [Abstract][Full Text] [Related]
5. Metabolomic profiling of amino acids study reveals a distinct diagnostic model for diabetic kidney disease.
Wang J; Zhou C; Zhang Q; Liu Z
Amino Acids; 2023 Nov; 55(11):1563-1572. PubMed ID: 37736814
[TBL] [Abstract][Full Text] [Related]
6. Metabolomics reveal mitochondrial and fatty acid metabolism disorders that contribute to the development of DKD in T2DM patients.
Li L; Wang C; Yang H; Liu S; Lu Y; Fu P; Liu J
Mol Biosyst; 2017 Oct; 13(11):2392-2400. PubMed ID: 28956034
[TBL] [Abstract][Full Text] [Related]
7. Serum metabolomics detected by LDI-TOF-MS can be used to distinguish between diabetic patients with and without diabetic kidney disease.
Qian F; Zhao L; Zhang D; Yu M; Zhou W; Jin J
FEBS Open Bio; 2023 Oct; 13(10):1844-1858. PubMed ID: 37525631
[TBL] [Abstract][Full Text] [Related]
8. Urine metabolomics reveals biomarkers and the underlying pathogenesis of diabetic kidney disease.
Luo M; Zhang Z; Lu Y; Feng W; Wu H; Fan L; Guan B; Dai Y; Tang D; Dong X; Yun C; Hocher B; Liu H; Li Q; Yin L
Int Urol Nephrol; 2023 Apr; 55(4):1001-1013. PubMed ID: 36255506
[TBL] [Abstract][Full Text] [Related]
9. Extracellular vesicles metabolic changes reveals plasma signature in stage-dependent diabetic kidney disease.
Pan Y; Yang H; Chen T; Jin J; Ruan L; Hu L; Chen L
Ren Fail; 2022 Dec; 44(1):1840-1849. PubMed ID: 36368309
[TBL] [Abstract][Full Text] [Related]
10.
Lin HT; Cheng ML; Lo CJ; Lin G; Lin SF; Yeh JT; Ho HY; Lin JR; Liu FC
J Clin Med; 2019 Jun; 8(6):. PubMed ID: 31248127
[TBL] [Abstract][Full Text] [Related]
11. Integration of metabolomics and peptidomics reveals distinct molecular landscape of human diabetic kidney disease.
Jiang X; Liu X; Qu X; Zhu P; Wo F; Xu X; Jin J; He Q; Wu J
Theranostics; 2023; 13(10):3188-3203. PubMed ID: 37351171
[TBL] [Abstract][Full Text] [Related]
12. Atherogenic Index of Plasma as an Early Marker of Chronic Kidney Disease and Liver Injury in Type 2 Diabetes.
Li H; Miao X; Zhong J; Zhu Z
Clin Med Insights Endocrinol Diabetes; 2024; 17():11795514241259741. PubMed ID: 38859965
[TBL] [Abstract][Full Text] [Related]
13. Metabolomic Investigation of Blood and Urinary Amino Acids and Derivatives in Patients with Type 2 Diabetes Mellitus and Early Diabetic Kidney Disease.
Mogos M; Socaciu C; Socaciu AI; Vlad A; Gadalean F; Bob F; Milas O; Cretu OM; Suteanu-Simulescu A; Glavan M; Ienciu S; Balint L; Jianu DC; Petrica L
Biomedicines; 2023 May; 11(6):. PubMed ID: 37371622
[TBL] [Abstract][Full Text] [Related]
14. Association of Serum Total Bilirubin and Uric Acid with Low Glomerular Filtration Rate Diabetic Kidney Disease in Type 2 Diabetic Patients.
Tafese R; Genet S; Addisu S
Diabetes Metab Syndr Obes; 2022; 15():3993-3999. PubMed ID: 36575681
[TBL] [Abstract][Full Text] [Related]
15. The Role of Gut Microbiota and Microbiota-Related Serum Metabolites in the Progression of Diabetic Kidney Disease.
Zhang Q; Zhang Y; Zeng L; Chen G; Zhang L; Liu M; Sheng H; Hu X; Su J; Zhang D; Lu F; Liu X; Zhang L
Front Pharmacol; 2021; 12():757508. PubMed ID: 34899312
[No Abstract] [Full Text] [Related]
16. Identification of Potential Serum Metabolic Biomarkers of Diabetic Kidney Disease: A Widely Targeted Metabolomics Study.
Zhang H; Zuo JJ; Dong SS; Lan Y; Wu CW; Mao GY; Zheng C
J Diabetes Res; 2020; 2020():3049098. PubMed ID: 32190695
[TBL] [Abstract][Full Text] [Related]
17. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease.
Lu YP; Zhang ZY; Wu HW; Fang LJ; Hu B; Tang C; Zhang YQ; Yin L; Tang DE; Zheng ZH; Zhu T; Dai Y
J Transl Med; 2022 Sep; 20(1):420. PubMed ID: 36104729
[TBL] [Abstract][Full Text] [Related]
19. Urinary microbiota and serum metabolite analysis in patients with diabetic kidney disease.
Yang Y; Ma C; Li S; Cai W; Dai W; Zhang X; Yin L; Donge Tang ; Liu F; Dai Y
Heliyon; 2023 Aug; 9(8):e17040. PubMed ID: 37521000
[TBL] [Abstract][Full Text] [Related]
20. Quantitative, Targeted Analysis of Gut Microbiota Derived Metabolites Provides Novel Biomarkers of Early Diabetic Kidney Disease in Type 2 Diabetes Mellitus Patients.
Balint L; Socaciu C; Socaciu AI; Vlad A; Gadalean F; Bob F; Milas O; Cretu OM; Suteanu-Simulescu A; Glavan M; Ienciu S; Mogos M; Jianu DC; Petrica L
Biomolecules; 2023 Jul; 13(7):. PubMed ID: 37509122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
